British Journal of Cancer

Article	Citations
Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial	181
Advancing radiomics from contrast-enhanced mammography in breast cancer	165
Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours	144
Investigation of the gut microbiome, bile acid composition and host immunoinflammatory response in a model of azoxymethane-induced colon cancer at discrete timepoints	141
Surveillance after childhood cancer: are survivors with an increased risk for cardiomyopathy regularly followed-up?	135
Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma	108
Correction to: Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort	106
Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer	105
Correction to: EGFR/Ras-induced CCL20 production modulates the tumour microenvironment	105
Proactive breast cancer risk assessment in primary care: a review based on the principles of screening	102
Years of life lost due to cancer in the United Kingdom from 1988 to 2017	98
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)	95
Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers	93
The EXO1/Polη/Polι axis as a promising target for miR-3163-mediated attenuation of cancer stem-like cells in non-small cell lung carcinoma	93
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours	92
Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis	91
Cancer therapy with decreased SARS-CoV-2 infection rates in cancer patients	90
Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition	89
Hepatitis B virus X protein promotes MAN1B1 expression by enhancing stability of GRP78 via TRIM25 to facilitate hepatocarcinogenesis	86
Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer	86
CD20 expression, TrkB activation and functional activity of diffuse large B cell lymphoma-derived small extracellular vesicles	85
Metastasis-associated fibroblasts in peritoneal surface malignancies	85
Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity	84
Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer	82
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer	80

Assessments of social vulnerability on laryngeal cancer treatment & prognosis in the US	77
Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer	75
Genomic ALK alterations in primary and relapsed neuroblastoma	75
Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing	74
VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis	71
A very-hot food and beverage thermal exposure index and esophageal cancer risk in Malawi and Tanzania: findings from the ESCCAPE case–control studies	70
Correction: YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT pathways	70
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)	68
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analy	67
Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours	67
Extruded small extracellular vesicles: splinters of circulating tumour cells may promote cancer metastasis?	66
Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value	64
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3	64
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer	63
Navigating therapeutic strategies: HPV classification in head and neck cancer	63
Identifying health conditions associated with an increased risk of pancreatic ductal adenocarcinoma at medium term in nationwide electronic health records of primary care physicians	62
Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities	62
The mental health impacts of receiving a breast cancer diagnosis: A meta-analysis	62
Metabolic adaptations in prostate cancer	60
DRP1 inhibition-mediated mitochondrial elongation abolishes cancer stemness, enhances glutaminolysis, and drives ferroptosis in oral squamous cell carcinoma	60
Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate	59
Long-term trends in incidence, characteristics and prognosis of screen-detected and interval cancers in women participating in the Dutch breast cancer screening programme	58
Identification of increased dedifferentiation along the Prom1+ cancer cells in Müllerian adenosarcoma with sarcomatous overgrowth	58
Hypoxia- and Postirradiation reoxygenation-induced HMHA1/ARHGAP45 expression contributes to cancer cell invasion in a HIF-dependent manner	58
Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study	57
Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma	57
Somatic hits in mismatch repair genes in colorectal cancer among non-seminoma testicular cancer survivors	55
The impact of the first 2 years of the COVID-19 pandemic on breast cancer diagnoses: a population-based study in England	54
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer	54
Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer	54
Albendazole inhibits colon cancer progression and therapy resistance by targeting ubiquitin ligase RNF20	53
Preclinical study of 212Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma	53
DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors	53
Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II st	53
Progress and priorities in reducing the time to cancer diagnosis	52
Oxaliplatin induces pyroptosis in hepatoma cells and enhances antitumor immunity against hepatocellular carcinoma	52
Cancer in Costello syndrome: a systematic review and meta-analysis	52
Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150	50
Deep learning analysis of histopathological images predicts immunotherapy prognosis and reveals tumour microenvironment features in non-small cell lung cancer	49
Emerging nanomedical strategies for direct targeting of pediatric and adult diffuse gliomas	49
Long-term use of antihypertensive medications, hypertension and colorectal cancer risk and mortality: a prospective cohort study	47
Expression and functions of long non-coding RNA NEAT1 and isoforms in breast cancer	47
Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification	46
Changes in circulating exosome molecular profiles following surgery/(chemo)radiotherapy: early detection of response in head and neck cancer patients	46
Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials	45
Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer	45
Protein markers of ovarian cancer and its subtypes: insights from proteome-wide Mendelian randomisation analysis	45
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer	45
PTBP1 drives c-Myc-dependent gastric cancer progression and stemness	45
A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer	44

Evidence into practice: a national cohort study of NICE-recommended oncological drug therapy utilisation among women diagnosed with invasive breast cancer in England	44
Optimizing adjuvant treatment strategies for non-pancreatic periampullary cancers	44
The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination	43
EEF1A2 promotes HIF1A mediated breast cancer angiogenesis in normoxia and participates in a positive feedback loop with HIF1A in hypoxia	42
Effect of risk-based screening for upper gastrointestinal cancers: a multi-center real-world study	42
Introduction and impact of routine whole genome sequencing in the diagnosis and management of sarcoma	42
Multistate models for the natural history of cancer progression	41
Nutritional status, body composition and chemotherapy dosing in children and young people with cancer: a systematic review by the SIOP nutrition network	41
Serum 25-hydroxyvitamin D concentrations and colorectal cancer incidence in adults with type 2 diabetes	41
Relation knowledge distillation 3D-ResNet-based deep learning for breast cancer molecular subtypes prediction on ultrasound videos: a multicenter study	40
Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial	40
Regional variations in hepatocellular carcinoma incidence, routes to diagnosis, treatment and survival in England	40
A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study	40
The Glasgow Microenvironment Score and risk and site of recurrence in TNM I–III colorectal cancer	40
The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy	40
A systematic review of microbial markers for risk prediction of colorectal neoplasia	39
Tissue factor in cancer-associated thromboembolism: possible mechanisms and clinical applications	39
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)	39
Adolescent dietary patterns in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study	39
Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer	38
APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation	38
Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic	38
Molecular pathways in post-colonoscopy versus detected colorectal cancers: results from a nested case–control study	37
Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia	37
The mediating role of combined lifestyle factors on the relationship between education and gastric cancer in the Stomach cancer Pooling (StoP) Project	37
High-throughput precision MRI assessment with integrated stack-ensemble deep learning can enhance the preoperative prediction of prostate cancer Gleason grade	37
Correction: Differential cellular origins of the extracellular matrix of tumor and normal tissues according to colorectal cancer subtypes	37
Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP/TAZ-Hedgehog signalling axis in pancreatic cancer	36
Immune evasion in lung metastasis of leiomyosarcoma: upregulation of EPCAM inhibits CD8+ T cell infiltration	36
Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases	36
Cancer risk in individuals with polydactyly: a Swedish population-based cohort study	36
A multimodal imaging study to highlight elastin-derived peptide pro-tumoral effect in a pancreatic xenograft model	36
MET exon 14 skipping mutation drives cancer progression and recurrence via activation of SMAD2 signalling	35
Manassantin A inhibits tumour growth under hypoxia through the activation of chaperone-mediated autophagy by modulating Hsp90 activity	35
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer	35
Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study	35
A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer	35
Correction: Targeting oncogenic microRNAs from the miR-371~373 and miR-302/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption	35
The prognostic value of MEK pathway–associated estrogen receptor signaling activity for female cancers	35
What do women think about having received their breast cancer risk as part of a risk-stratified NHS Breast Screening Programme? A qualitative study	34
Confidence bands in survival analysis	34
Capturing breast cancers’ copy-number landscape in routine pathology: Exploiting low-resolution, genome-wide sequencing to identify HRD and beyond	34
The prognostic impact of peritoneal tumour DNA in gastrointestinal and gynaecological malignancies: a systematic review	34
Correction: Modelled mortality benefits of multi-cancer early detection screening in England	34
Thinking inside the box: intracellular roles for complement system proteins come into focus	34
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer	34
Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer	34
Chromatin accessibility uncovers KRAS-driven FOSL2 promoting pancreatic ductal adenocarcinoma progression through up-regulation of CCL28	34
Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer	33
Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions	33
Correction: Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway	33
Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis	33
A metabolomic analysis of adiposity measures and pre- and postmenopausal breast cancer risk in the Nurses’ Health Studies	33
Cost-effectiveness of one-off upper abdominal CT screening as an add-on to lung cancer screening in England	33
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours	33
Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma	32
Glycometabolic reprogramming-mediated proangiogenic phenotype enhancement of cancer-associated fibroblasts in oral squamous cell carcinoma: role of PGC-1α/PFKFB3 axis	32
The in vitro dynamics of pseudo-vascular network formation	32
Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial	32
Oesophageal cancer awareness and anticipated time to help-seeking: results from a population-based survey	32
Cannabinoids induce cell death in leukaemic cells through Parthanatos and PARP-related metabolic disruptions	32
Routes to diagnosis for hepatocellular carcinoma patients: predictors and associations with treatment and mortality	32
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients	32
Transcriptomic and functional analyses reveal a tumour-promoting role for the IL-36 receptor in colon cancer and crosstalk between IL-36 signalling and the IL-17/ IL-23 axis	32
Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets	32
UK Biobank: a globally important resource for cancer research	32
Consultations for clinical features of possible cancer and associated urgent referrals before and during the COVID-19 pandemic: an observational cohort study from English primary care	32
Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin	32
Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial	32
Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients	32
50 years on and still very much alive: ‘Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics’	31
Sodium nitrite orchestrates macrophage mimicry of tongue squamous carcinoma cells to drive lymphatic metastasis	31
Correction: Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility	31
Regulatory non-coding somatic mutations as drivers of neuroblastoma	31
Immune checkpoint inhibitor combinations—current and emerging strategies	31
Hypoxia does not predict lack of benefit from adjuvant radiotherapy for patients with early stage breast cancer	31
Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study	31
Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer	31
Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors	31
DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance	31

VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models	31
Reply to Dr. Rafael Rosell: Shedding some light on the unresolved issue of YAP1 Ser397 phosphorylation in cancer	31
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial	30
HECTD3 regulates the tumourigenesis of glioblastoma by polyubiquitinating PARP1 and activating EGFR signalling pathway	30
A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing	30
Plasma extracellular vesicle circRNA signature and resistance to abiraterone in metastatic castration-resistant prostate cancer	30
Nonrandomised controlled trial in recurrent glioblastoma patients: the promise of autologous tumour lysate-loaded dendritic cell vaccination	30
Identification of diagnostic biomarkers in prostate cancer-related fatigue by construction of predictive models and experimental validation	30
Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study	30
Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations	30
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma	30
Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status	30
CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer	30
Correction to: The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care	30
Targeting oncogenic microRNAs from the miR-371~373 and miR-302/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption	30
Stroma AReactive Invasion Front Areas (SARIFA) and the tumour immune microenvironment in colorectal cancer	30
MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data	30
EIF4A3-negatively driven circular RNA β-catenin (circβ-catenin) promotes colorectal cancer progression via miR-197-3p/CTNND1 regulatory axis	30
Postdiagnosis physical activity is associated with improved survival in prostate cancer patients treated with surgery but not with radiation therapy	29
Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology	29
Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis	29
Preferences for multi-cancer tests (MCTs) in primary care: discrete choice experiments of general practitioners and the general public in England	29
Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk	29
Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer	29
Health benefits and harms of mammography screening in older women (75+ years)—a systematic review	29
Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma	29
Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function	29
Exosomal transfer of miR-181b-5p confers senescence-mediated doxorubicin resistance via modulating BCLAF1 in breast cancer	29
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer	29
Comparison of methods for cancer stem cell detection in prognosis of early stages NSCLC	28
Cancer-associated fibroblasts expressing fibroblast activation protein and podoplanin in non-small cell lung cancer predict poor clinical outcome	28
Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1)	28
Response to: Genetic risk scores may compound rather than solve the issue of prostate cancer overdiagnosis (BJC-LT3342090)	28
Obituary – Margaret Wilcox	28
Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up	28
Mutation of the proline P81 into a serine modifies the tumour suppressor function of the von Hippel–Lindau gene in the ccRCC	28
Editorial Expression of Concern: Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential	28
Single-cell sequencing of PIT1-positive pituitary adenoma highlights the pro-tumour microenvironment mediated by IFN-γ-induced tumour-associated fibroblasts remodelling	28
The role of genetic predisposition in cardiovascular risk after cancer diagnosis: a matched cohort study of the UK Biobank	28
The National COVID Cancer Antibody Survey: a hyper-accelerated study proof of principle for cancer research	28
Understanding genetic architecture of breast cancer: how can proteome-wide association studies contribute?	27
Artificial intelligence-driven microRNA signature for early detection of gastric cancer: discovery and clinical functional exploration	27
AKT/mTOR as a targetable hub to overcome multimodal resistance to EGFR inhibitors in oesophageal squamous cell carcinoma	27
Correction: DKC1 enhances angiogenesis by promoting HIF-1α transcription and facilitates metastasis in colorectal cancer	27
Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study	27
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies	27
ctDNA variations according to treatment intensity in first-line metastatic colorectal cancer	27
A study of subjective memory impairment in long-term testicular cancer survivors	26
Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients	26
Anti-angiogenic therapy using the multi-tyrosine kinase inhibitor Regorafenib enhances tumor progression in a transgenic mouse model of ß-cell carcinogenesis	26
A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma	26
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells	26
Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition	26
Epithelial−mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer	26
Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis	26
Associations between serum glucose, insulin, insulin resistance and the risk of incident primary liver cancer or chronic liver disease mortality: a nested case–control study	26
Hypoxia-inducible factor 3α1 increases epithelial-to-mesenchymal transition and iron uptake to drive colorectal cancer liver metastasis	26
Role of 18F-FDG-PET/CT in the initial staging of very high-risk Ewing Sarcoma in a prospective multicentric Phase II Study: Is there still a place for bone marrow sampling?	25
Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer	25
The long noncoding RNA lncZBTB10 facilitates AR function via S-palmitoylation to promote prostate cancer progression and abiraterone resistance	25
Regulatory T cells induce a suppressive immune milieu and promote lymph node metastasis in intrahepatic cholangiocarcinoma	25
Angiogenin and plexin-B2 axis promotes glioblastoma progression by enhancing invasion, vascular association, proliferation and survival	25
Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers	25
Prognostic value of post-operative iron biomarkers in colorectal cancer: population-based patient cohort	25
Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine	25
Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer	24
Hormone replacement therapy and cancer mortality in women with 17 site-specific cancers: a cohort study using linked medical records	24
Genome-wide polygenic risk scores for colorectal cancer have implications for risk-based screening	24
Breast density is strongly associated with multiparametric magnetic resonance imaging biomarkers and pro-tumorigenic proteins in situ	24
Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential	24
Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy	24
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2	24
Breast cancer metastasis progression is associated with elevated activity of kynurenine monooxygenase and kynureninase	24
Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus	24
Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer	24
Attention-based deep learning for breast lesions classification on contrast enhanced spectral mammography: a multicentre study	24
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?	24
Modelled mortality benefits of multi-cancer early detection screening in England	24
Comment on: “Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial”	24
Intratumour heterogeneity, from hypothesis to the clinic	24
Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer	23
β-blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis	23
The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study	23
The epigenetic basis of hepatocellular carcinoma – mechanisms and potential directions for biomarkers and therapeutics	23
Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer	23
Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies	23
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION	23
Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment	23
Platelets induce CD39 expression in tumor cells to facilitate tumor metastasis	23
Clinical assessment of the miR-34, miR-200, ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and prognosis in resected NSCLC	23
A liquid biopsy signature for predicting early recurrence in patients with gastric cancer	23
Correction: TIGIT antibody with PVR competitive ability enhances cancer immunotherapy and capable of eliciting anti-tumour immune memory	23
LHX2 facilitates the progression of nasopharyngeal carcinoma via activation of the FGF1/FGFR axis	22
Multicenter evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic	22
Semi-mechanistic efficacy model for PARP + ATR inhibitors—application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs	22